Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gimme Care vs HealthRX

Gimme Care
Graded #23

Lower grade

vs+1.5
HealthRX
Graded #8

Higher grade

The verdict

HealthRX takes it — 86.1/100 to 84.6/100, but only just.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it. Gimme Care is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGimme Care +4
89
85
Dose & formulationHealthRX +10
80
90
Clinical oversightHealthRX +3
84
87
Labs & monitoringEven
82
82
FulfillmentGimme Care +1
87
86
Contract termsEven
85
85
Gimme Care · left barHealthRX · right bar

The numbers

MetricGimme CareHealthRX
WeighScore84.6/10086.1/100
GradeBB
Scorecard rank#23#8
Semaglutide$130/mo$189/mo
Tirzepatide$163/mo$349/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Gimme Care

Graded #23 · B

Strengths

  • $130 sema / $163 tirz
  • All 50 states, LegitScript-verified
  • Both molecules

Where it loses points

  • Not the cheapest tier
  • Injection-only
  • Monitoring detail limited
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard